Representative Examples of

Commercial Results

ENTOCORT EC®

• US commercial rights acquired from AZ in 2005

• Indicated for mild to moderate Chron’s disease

• Drug demand was flat with AZ

• Implemented a commercial team targeting top institutions employing expanded promotion and account support

• Growth with no new clinical data or indications

$US Sales (in Millions)

LOTRONEX®

• Global rights acquired in 2008 from GSK

• Indicated for women with severe IBS-D

• Withdrawn from market by GSK

• Reinstated with highest-level REMS program

• With careful management, REMS was favorably modified

• Restoration of product growth

$US Sales (in Millions)

PROLEUKIN®

• US commercial rights acquired from Novartis in 2009 (following its acquisition of Chiron)

• Indicated for metastatic renal cancer and melanoma

• Drug demand was falling

• Implemented a commercial team targeting top 100+ institutions employing expanded promotion and account support

$US Sales (in Millions)

COPIKTRA®

• Global rights acquired in ’20 from Verastem

• Indicated for CLL/SLL

• Optimization of commercial mix results in high growth in ’21 and ’22

• Continued to grow despite FDA attack on PI3Ks and ODAC on COPIKTRA

• Focus on information and high prescribers restored product growth for ’24